Neurodegenerative ailments are escalating in parallel to the lengthening of survival. The management of Alzheimer’s illness (AD) and other dementias, Parkinson’s illness (PD) and PD-associated problems, and motor neuron diseases (MND), is mostly targeted to motor and cognitive impairment, with specific care for essential functions such as breathing and feeding. Places covered: The present assessment focuses on chronic discomfort in most important neurodegenerative ailments, addressing present proof on discomfort therapeutic management, discomfort frequency and clinical attributes, and probable pathophysiological mechanisms. The search on PubMed had no time limits and was performed by looking for the following crucial difficulties: discomfort, dementia, Alzheimer illness, Parkinson’s illness, extrapyramidal problems, motoneuronal illness, Amyotrophic lateral sclerosis, FXTAS, frequency, pathophysiology, therapies, therapy, efficacy, opioids, side effects. No controlled therapeutic trials and suggestions are presently obtainable. The effects of present therapies such as L-Dopa or riluzole on discomfort symptoms are not clear. Emerging evidences on the probable anti-nociceptive effects of cannabis or botulinum toxin may possibly be obtainable quickly. Specialist commentary: Discomfort requirements to be greater evaluated and completely regarded as in the international management of neurodegenerative illness because a extra focused remedy may perhaps have a good influence on the international burden of these devastating problems.